Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 1:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 9,926 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Single-arm Clear all
Terminated Not applicable Interventional Results available

Tumor Detection Using Iodine-131-Labeled Monoclonal Antibody 8H9

NCT00582608
View directory record Official record
Conditions
CNS Cancer, Neuroblastoma, Sarcoma
Interventions
131I-8H9, 8H9
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
1 Year to 50 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 1, 2017 · Synced Oct 31, 2026, 1:31 AM EDT
Active, not recruiting Phase 2 Interventional

Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery

NCT03493425
View directory record Official record
Conditions
Stage III Sinonasal Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Sinonasal Squamous Cell Carcinoma AJCC v7
Interventions
Carboplatin, Cisplatin, Docetaxel, Image Guided Radiation Therapy, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Questionnaire Administration, Therapeutic Conventional Surgery
Drug · Radiation · Other + 1 more
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
154
States / cities
Tucson, Arizona • Fort Smith, Arkansas • Palo Alto, California + 111 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 31, 2026, 1:31 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Toll-like Receptor (TLR) 7 Agonist, Cyclophosphamide, and Radiotherapy for Breast Cancer With Skin Metastases

NCT01421017
View directory record Official record
Conditions
Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer
Interventions
Radiation, Imiquimod, Cyclophosphamide
Radiation · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 18, 2021 · Synced Oct 31, 2026, 1:31 AM EDT
Completed Not applicable Interventional

An Outpatient Study of Automated Blood Glucose Control With an Insulin-Only Bionic Pancreas

NCT02536950
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Fixed set point, Variable set point
Device
Lead sponsor
Bruce A. Buckingham
Other
Eligibility
18 Years to 44 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 21, 2018 · Synced Oct 31, 2026, 1:31 AM EDT
Completed Not applicable Interventional

A Pilot Study: Treatment of Achilles Tendinopathy With Platelet-Rich Plasma Therapy

NCT01911650
View directory record Official record
Conditions
Achilles Tendinitis
Interventions
Autologous Platelet Rich Plasma, Ultrasound Imaging, Quality of Life Questionnaires
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 18, 2019 · Synced Oct 31, 2026, 1:31 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Pilot Study of OMEGA-3 and Vitamin D in High-Dose in Type I Diabetic Patients

NCT03406897
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Hypoglycemia, Diabetes Mellitus, Diabetes, Autoimmune
Interventions
Cholecalciferol, Omega 3 fatty acid
Drug
Lead sponsor
Rodolfo Alejandro
Other
Eligibility
6 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 31, 2026, 1:31 AM EDT
Completed Not applicable Interventional Results available

Diabetes Homeless Medication Support Single Arm Treatment Development Trial

NCT04678284
View directory record Official record
Conditions
Type 2 Diabetes, Homeless Persons
Interventions
Diabetes Homeless Medication Support (D-Homes)
Behavioral
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 31, 2026, 1:31 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Consortium for Optimized Integration of Bio-Artificial Blood Components for Adaptive Resuscitation Therapy

NCT05756426
View directory record Official record
Conditions
Hemorrhage, Hemodynamic Instability
Interventions
Prospective
Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 88 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 31, 2026, 1:31 AM EDT
Not listed Phase 4 Interventional

Oxytocin Bolus Versus Infusion in Elective Cesarean Section"

NCT05236985
View directory record Official record
Conditions
Elective Cesarean Section
Interventions
Oxytocin bolus or oxytocin infusion
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Mar 15, 2024 · Synced Oct 31, 2026, 1:31 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Relative Bioavailability, Safety, and Tolerability of Single-dose Sotrovimab Injection in Adults (COSMIC)

NCT05280717
View directory record Official record
Conditions
Covid19
Interventions
sotrovimab
Biological
Lead sponsor
Vir Biotechnology, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
316 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
10
States / cities
Riverside, California • Atlantis, Florida • Edgewater, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 31, 2026, 1:31 AM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma

NCT03290950
View directory record Official record
Conditions
Multiple Myeloma
Interventions
daratumumab, carfilzomib, lenalidomide, dexamethasone
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 31, 2026, 1:31 AM EDT
Completed Phase 1 Interventional Results available

Dasatinib in Combination With Revlimid (and Dexamethasone)

NCT00560391
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Dasatinib, 70 mg + Lenalidomide, 15 mg + Dexamethasone, 40 mg, Dasatinib, 70 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg, Dasatinib, 100 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg, Dasatinib, 100 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg, Dasatinib, 140 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 4, 2016 · Synced Oct 31, 2026, 1:31 AM EDT
Not listed Phase 2 Interventional

Metastatic Solid Cancer Clinical Trial

NCT04739618
View directory record Official record
Conditions
Metastatic Cancer
Interventions
Keytruda Injectable Product, Yervoy Injectable Product, GM-CSF, Non-ablative Cryosurgical freezing
Drug · Procedure
Lead sponsor
ImmunSYS, LLC
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Scottsdale, Arizona • Miami Lakes, Florida
Source: ClinicalTrials.gov public record
Updated Jul 23, 2024 · Synced Oct 31, 2026, 1:31 AM EDT
Completed Not applicable Interventional Results available

AMBULATE Continued Access Protocol to Evaluate the Cardiva Mid-Bore Venous Vascular Closure System (VVCS)

NCT03573206
View directory record Official record
Conditions
Surgical Wound
Interventions
Cardiva Mid-Bore Venous Vascular Closure Device (VVCS)
Device
Lead sponsor
Cardiva Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Atlanta, Georgia • Ridgewood, New Jersey • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 10, 2023 · Synced Oct 31, 2026, 1:31 AM EDT
Terminated Phase 1 Interventional

Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers

NCT02734615
View directory record Official record
Conditions
Advanced or Metastatic ER+ Breast Cancer
Interventions
LSZ102, LEE011, BYL719
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2022 · Synced Oct 31, 2026, 1:31 AM EDT
Completed Phase 2 Interventional Results available

Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma

NCT02654990
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Panobinostat Capsules, Bortezomib Injection, Dexamethasone tablets
Drug
Lead sponsor
pharmaand GmbH
Industry
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
9
States / cities
Fayetteville, Arkansas • Los Angeles, California • Fort Collins, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2024 · Synced Oct 31, 2026, 1:31 AM EDT
Active, not recruiting Phase 2 Interventional Results available

A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer

NCT03246347
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma
Interventions
ADT+Docetaxel+Enzalutamide
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 31, 2026, 1:31 AM EDT
Recruiting Phase 2Phase 3 Interventional

A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease

NCT06328608
View directory record Official record
Conditions
Fabry Disease
Interventions
PRX-102 1 mg/kg every two weeks
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
2 Years to 17 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
6
States / cities
Phoenix, Arizona • Atlanta, Georgia • Iowa City, Iowa + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 31, 2026, 1:31 AM EDT
Completed No phase listed Observational

Mechanisms of Increased Ambulatory Blood Pressure in Patients With Intradialytic Hypertension

NCT01862497
View directory record Official record
Conditions
Intradialytic Hypertension
Interventions
Carvedilol vs. Prazosin
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Oct 31, 2026, 1:31 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Engineering an Online STI Prevention Program: CSE2

NCT03408743
View directory record Official record
Conditions
Alcohol Consumption, Sexually Transmitted Diseases
Interventions
Knowledge Alone, Self-efficacy alone, Perceived benefits alone, Benefits and self-efficacy, Injunctive norms alone, Injunctive norms and self-efficacy, Injunctive norms and benefits, Injunctive norms, benefits, self-efficacy, Descriptive norms alone, Descriptive norms and self-efficacy, Descriptive norms and perceived benefits, Descriptive norms, benefits, self-efficacy, Descriptive norms and injunctive norms, Descriptive and injunctive norms, self-efficacy, Descriptive and injunctive norms, and benefits, Descriptive & injunctive norms, benefits, efficacy, Expectancies alone, Expectancies and self-efficacy, Expectancies and perceived benefits, Expectancies, benefits, self-efficacy, Expectancies and injunctive norms, Expectancies, injunctive norms, self-efficacy, Expectancies, injunctive norms, and benefits, Expectancies, injunctive norms, benefits, efficacy, Expectancies and descriptive norms, Expectancies, descriptive norms, & self-efficacy, Expectancies, descriptive norms, benefits, Expectancies, descriptive norms, benefits, efficacy, Expectancies, descriptive and injunctive norms, Expectancies, descriptive & injunctive norms, efficacy, Expectancies, descriptive & injunctive norms, benefits, Expectancies, descriptive & injunctive, benefits, efficacy
Behavioral
Lead sponsor
Penn State University
Other
Eligibility
18 Years to 30 Years
Enrollment
2,946 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
4
States / cities
Fresno, California • Fargo, North Dakota • Murfreesboro, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2019 · Synced Oct 31, 2026, 1:31 AM EDT
Recruiting Not applicable Interventional

Evaluating Clinical Hiatal Hernia Outcomes Using OviTex®

NCT07070115
View directory record Official record
Conditions
Hiatal Hernia
Interventions
OviTex Reinforced Tissue Matrix
Device
Lead sponsor
Tela Bio Inc
Industry
Eligibility
22 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
5
States / cities
Mobile, Alabama • Denver, Colorado • Lexington, Kentucky + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 31, 2026, 1:31 AM EDT
Completed Not applicable Interventional

Ayurveda Diet & Lifestyle Protocol for Type 2 Diabetes: A Feasibility Study

NCT07400276
View directory record Official record
Conditions
Type 2 Diabetes Mellitus (T2DM)
Interventions
Maharishi Ayurveda Lifestyle Program
Behavioral
Lead sponsor
Maharishi International University
Other
Eligibility
18 Years to 70 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Asheville, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 31, 2026, 1:31 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Comparing UroLift Experience Against Rezūm

NCT04338776
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
UroLift, Rezum
Device
Lead sponsor
NeoTract, Inc.
Industry
Eligibility
50 Years and older · Male only
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
7
States / cities
Los Angeles, California • Royal Oak, Michigan • Garden City, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 31, 2026, 1:31 AM EDT
Completed Not applicable Interventional

Physiatrist Ergonomic Intervention on Work Related Musculoskeletal Pain in Surgeons

NCT05946018
View directory record Official record
Conditions
Musculoskeletal Pain, Work Related Stress, Quality of Life, Grip
Interventions
Educational video on ergonomics, Verbal physical therapy coaching sessions
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
Not listed
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Oct 31, 2026, 1:31 AM EDT